91361-79-4

Upstream product

• 91361-78-3 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 
• 91373-91-0 (3-chloro-4-dimethylthiocarbamoyloxyphenyl)acetic acid methyl ester 
• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 
• 33697-81-3 (3-chloro-4-hydroxy-phenyl)-acetic acid 

Downstream Products

• 393186-02-2 3-chloro-4-[2-[[(1,1-dimethylethoxy)carbonyl]-amino]-ethylthio]benzeneacetic acid methyl ester 
• 194608-89-4 {3-chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 870289-05-7 [3-chloro-4-(3,5-dibromobenzylsulfanyl)phenyl]acetic acid methyl ester 
• 890137-68-5 [4-(4,4''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-ylmethylsulfanyl)-3-chloro-phenyl]-acetic acid methyl ester 
• 870520-89-1 (3-chloro-4-cyanomethylsulfanyl-phenyl)-acetic acid methyl ester 
• 851529-15-2 {3-chloro-4-[2-hydroxy-3-(4-trifluoromethyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 

Relevant academic research and scientific papers

1,3,5-Trisubstituted aryls as highly selective PPARδ agonists

A series of highly potent and selective PPARδ agonists is described using the known non-selective ligand GW2433 as a structural template. Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with other PPAR subtypes up to 10 μM, making it a useful tool in studying the biological effects of selective PPARδ activation.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

Synthesis of tritium labelled L783483 - A PPARδ ligand

The potent peroxisome proliferator-activated receptor (PPAR) δ ligand L783483 (3-chloro-4-(3-(7-propyl-3-trifluoromethyl-benzisoxazol-6-oxy) pro-pylsulfanyl)phenylacetic acid) has been labelled with tritium via selective tritium/bromine exchange of 5-brom

Identification of a series of PPARγ/δ dual agonists via solid-Phase parallel synthesis

We have developed a general solid-phase synthesis for identification of PPAR ligands. Synthesis of a 480-member library led to the identification of a potent PPARγ/δ dual agonist 23. Compound 23 showed good plasma exposure in rats and demonstrated antihyp